-

Dexcom Publishes Annual Sustainability Report

  • Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures including company’s first Sustainability Accounting Standards Board (SASB) index

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its third annual Sustainability Report. This report highlights Dexcom’s mission-driven efforts and provides updates on the environmental, social, and governance (ESG) initiatives progressing across the organization.

“At Dexcom, we remain focused on how we can better serve our stakeholders, including customers, employees, caregivers, investors, and communities,” said Kevin Sayer, chairman, president and CEO of Dexcom. “From broadening global access to our technology, advocating for the diabetes community, and supporting and developing our passionate and diverse employee base, we are proud of our accomplishments while embracing the need for continued progress toward the ambitious mission that motivates us.”

Dexcom’s sustainability initiatives are overseen by the Board of Directors and integrated as foundational elements of the company’s business strategy and mission. The annual report is framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.

Highlights from this year’s report include:

  • Publishing Dexcom’s first Sustainability Accounting Standards Board (SASB) index to improve ESG disclosure
  • Simplifying and expanding access to Dexcom CGM technology through payer negotiations, new product introductions, and clinical outcomes
  • Providing incremental disclosure around employee engagement and the makeup of Dexcom’s workforce
  • Committing to greater visibility on the organization’s emissions profile and climate-related disclosure

Dexcom’s Annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Annual Sustainability Report. All data in the report reflects calendar year 2021, unless noted otherwise.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and...

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,...
Back to Newsroom